- Pharmaceutical Executive: September 2025
- Volume 45
- Issue 7
Can AI Point the Way?
Coverage highlights from the September issue of Pharmaceutical Executive offer another example of the accelerated convergence—and future hope—of AI and healthcare.
Chronicling the rise of artificial intelligence (AI) in the biopharma industry has become, almost organically, a content-rich coverage “beat” here at Pharmaceutical Executive for the last year or two. From AI-focused Q&As and videos
One of our guest columnists, for example, outlines
But, most notably this month, is a special spotlight and perspective on the topic as captured in our
Not mentioned in the feature is an interesting insight Hudson conveyed to Christel about the future of modern innovation. The Sanofi CEO, who, with Bill Gates, co-chairs the Gates Foundation CEO Roundtable to boost global medicine access, remembers the tech visionary predicting that all the innovation accumulated over the last 100 years—the impact and volume—will occur on that same scale in just the next five years.
If indeed true, for pursuits in the life sciences, it will be fascinating to watch just how much AI can help trap lightning in a bottle—and translate that window of innovation into the breakthrough treatments of tomorrow. We’ll be here to capture it all.
Thanks for reading.
Mike Hennessy Jr. is Chairman and CEO of MJH Life Sciences
Articles in this issue
about 1 month ago
Pharmaceutical Executive: September 2025 Interactive Digital Editionabout 1 month ago
Turning AI Pilots into Enterprise Valueabout 1 month ago
Paul Hudson: A Mindset for Miraclesabout 1 month ago
How AI is Shaping KOL and DOL Identificationabout 1 month ago
From Lab to Market: Tracking Today’s Shifting Pathways for Biotechabout 1 month ago
Beyond the Pitch: Tapping Synergies in Earned Media Engagementabout 1 month ago
What Innovation in PBM Management Really Looks Likeabout 2 months ago
Measuring the ROI of SPP Adherence ProgramsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

